Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Determine if genotype-directed neoadjuvant chemoradiation, using information from the
thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging
in high risk patients compared to historical controls.